Use of IP Chemotherapy in Ovarian Cancer: The Critical Questions THE GONZALEZ/GREEN/MUGGIA ARTICLE REVIEWED

被引：0
|
作者：
Trimble, Edward L. [1 ]
Fujiwara, Keiichi [2 ]
Marth, Christian [3 ]
Abrams, Jeffrey [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[3] Innsbruck Med Univ Hosp, Innsbruck, Austria
来源：
ONCOLOGY-NEW YORK | 2011年 / 25卷 / 02期
关键词：
INTRAPERITONEAL CHEMOTHERAPY; SURVIVAL; SURGERY;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：170 / 174
页数：3
相关论文
共 31 条
  • [1] Advanced Prostate Cancer: New Agents, New Questions THE RUCH AND HUSSAIN ARTICLE REVIEWED
    Dorff, Tanya B.
    Pinski, Jacek
    ONCOLOGY-NEW YORK, 2011, 25 (06): : 509 - 512
  • [2] Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions
    Onda, Takashi
    Yoshikawa, Hiroyuki
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (07) : 1053 - 1067
  • [3] Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer
    Wright, Alexi A.
    Cronin, Angel
    Milne, Dana E.
    Bookman, Michael A.
    Burger, Robert A.
    Cohn, David E.
    Cristea, Mihaela C.
    Griggs, Jennifer J.
    Keating, Nancy L.
    Levenback, Charles F.
    Mantia-Smaldone, Gina
    Matulonis, Ursula A.
    Meyer, Larissa A.
    Niland, Joyce C.
    Weeks, Jane C.
    O'Malley, David M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (26) : 2841 - +
  • [4] Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer
    Meyer, Larissa A.
    Cronin, Angel M.
    Sun, Charlotte C.
    Bixel, Kristin
    Bookman, Michael A.
    Cristea, Mihaela C.
    Griggs, Jennifer J.
    Levenback, Charles F.
    Burger, Robert A.
    Mantia-Smaldone, Gina
    Matulonis, Ursula A.
    Niland, Joyce C.
    O'Malley, David M.
    Wright, Alexi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (32) : 3854 - +
  • [5] Neoadjuvant Chemotherapy in Ovarian Cancer: Are There Racial Disparities in Use and Survival?
    Amin, Saber A.
    Collin, Lindsay J.
    Setoguchi, Soko
    Satagopan, Jaya M.
    de Meritens, Alexandre Buckley
    Bandera, Elisa V.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (02) : 175 - 182
  • [6] Survival and recurrence after intraperitoneal chemotherapy use: Retrospective review of ovarian cancer hospital registrydata
    Adambekov, Shalkar
    Lopa, Samia
    Edwards, Robert P.
    Lemon, Lara
    Wang, Shu
    Taylor, Sarah E.
    Orr, Brian
    Linkov, Faina
    CANCER MEDICINE, 2020, 9 (20): : 7388 - 7397
  • [7] Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States
    Melamed, Alexander
    Hinchcliff, Emily M.
    Clemmer, Joel T.
    Bregar, Amy J.
    Uppal, Shitanshu
    Bostock, Ian
    Schorge, John O.
    del Carmen, Marcela G.
    Rauh-Hain, J. Alejandro
    GYNECOLOGIC ONCOLOGY, 2016, 143 (02) : 236 - 240
  • [8] USE OF AN IMPLANTABLE CATHETER SYSTEM FOR INTRAPERITONEAL CHEMOTHERAPY IN OVARIAN-CANCER
    BRANDNER, P
    NEIS, KJ
    ARTIFICIAL ORGANS, 1994, 18 (04) : 328 - 330
  • [9] Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature
    Gadducci, A.
    Conte, P. F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (05) : 943 - 953
  • [10] A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer
    Chiva, Luis M.
    Gonzalez-Martin, Antonio
    GYNECOLOGIC ONCOLOGY, 2015, 136 (01) : 130 - 135
1234